Can a Triple-Drug combo outsmart resistant leukemia?

NCT ID NCT07755202

Not yet recruiting Disease control Sponsor: Florian Kuchenbauer Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether adding gilteritinib to the standard drugs azacitidine and venetoclax can help adults with a type of acute myeloid leukemia (AML) that has returned or stopped responding to prior treatment. Participants receive the three-drug combination in repeated 28-day cycles for at least two cycles, with daily gilteritinib and azacitidine plus venetoclax on days 1-7. The study aims to see if this approach improves remission rates and to assess its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of gilteritinib, azacitidine, and venetoclax
What this could lead to: If effective, this combination could offer a new treatment option for AML patients whose cancer has stopped responding to standard therapy, potentially improving remission rates.
What could go wrong: This is a small phase 2 trial, so results may not be conclusive. The combination may cause significant side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA AML WITH FLT3 MUTATION

Contacts and locations

Locations

Vancouver General Hospital

Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.